Today's seminar is the first in a series of five hepatocyte seminars that BD will present throughout 2010 and 2011.

The upcoming titles and dates are as follows:
- Effect of BD Matrigel™ matrix overlay on hepatocyte health and CYP induction: November 10, 2010
- CYP induction assays in plated hepatocytes - CYP activity and mRNA analysis: January 12, 2011
- Plated hepatocytes for longer term metabolic stability assays: March 9, 2011
- Drug transport efflux and uptake assays using plated and suspension hepatocytes: May 5, 2011
Today’s Topics

• Overview of hepatocyte structure and physiology – Liver Basics
• Hepatocyte applications and products
• Thawing and plating methods for platable cryopreserved hepatocytes
• Sandwich cultures
• BD Gentest™ high viability recovery medium for thawing and plating cells
The liver weighs ~1200 to 1500 gm. It is 1/50 of the total adult weight. Diseases such as liver cirrhosis can increase the weight of liver >6x.

Structure:
- 2 major lobes, left and right, separated by the round and falciform ligaments.
- 2 smaller lobes- the caudate lobe and the quadrate lobe, separated by gallbladder fossa and the inferior vena cava fossa.
- The Gall bladder is connected to the liver and a common bile duct delivers bile from the liver and into the duodenum.
The Liver—Its Blood Supply

- Has a Dual blood supply:
  - Portal vein: Provides 75% of blood flow (1500 mL/min) to the liver. Receiving blood from small intestine, stomach, pancreas and spleen such that liver is the first site to receive nutrients absorbed from intestine.
  - Hepatic artery: 25% of blood flow. This is the oxygenated source.
  - Portal vein and hepatic artery blood empty and mix together in the sinusoids.

- Sinusoids are irregular vascular channels lined with a boundary of endothelial cells.

- Hepatocytes line the sinusoids around the endothelial cells.
The Liver—The Biliary System

• Function: Elimination pathway
  – It helps to remove lipophilic compounds out of the hepatocyte

• Structure:
  – The biliary system is a series of channels that conveys bile which is a secretory product of hepatocytes, from lumen to small intestine.
  – Bile canaliculus is not a “duct” per se. It is the intercellular space between adjacent hepatocytes that is defined by tight junctions.
  – Small ducts anastomose into larger and larger ducts to eventually form the common bile duct.

• The Gall Bladder serves as a place to store excess bile.
Liver—Physiology

- Hepatic Lobule: comprised of portal triad and central vein. Differential function based on hepatocyte location within lobule.

- Hepatic acinus- orients the cells to vascular system.
  - Zone 1: (Periportal) nearest to arterioles, oxygenated, most metabolically active, first to “see”/absorb potential toxins. Oxidative metabolism—generation of ATP.
  - Zone 2
  - Zone 3: Pericentrally localized hepatocytes, more hypoxic: synthesis of glycogen, fatty acid and bile salts. Detoxification by reduction.
Hepatobiliary Transport

Canulicular or Apical Membrane

Bile Canaliculus

Sinusoidal or Basolateral Membrane

NTCP

OATPs

OATs

OCTs

BSEP

MDR3

MDR1

MRP2

MRP3

MRP6

MRP5

Tight Junctions

ATP

ATP

ATP

ATP

ATP

ATP

The Liver—Physiology

Cell types:

- Hepatocytes – Comprises the bulk of liver (~80%). Responsible for Metabolism.
- Endothelial cells – Form loose layer of cells around sinusoids. Lack typical basement membrane of vascular endothelium. Have role in lipoprotein metabolism.
- Kupffer cells – Macrophages; modulate immune response through release of mediators and cytotoxic agents. Associated with endothelium.
- Perisinusoidal fat-storing cells (Lipocytes or Ito cells) – Located in sinusoids. Contribute to hepatic fibrosis with liver injury.
- Pit cells: Natural Killer lymphocytes associated with endothelium, highly mobile (least common cell type in liver).
Liver Function—Metabolism and Energy Production

- The liver is the primary organ for metabolism
  - Metabolizes carbohydrates, fats and protein
  - Synthesizes lipoproteins, cholesterol and phospholipids
  - Produces blood coagulation factors
  - Stores energy: fatty acids/glycerol and glycogen
  - Maintains constant blood-glucose levels
    (glycogenesis $\leftrightarrow$ glycogenolysis)
  - Bile Production
  - Converts NH$_3$ (toxic byproduct of amino acid breakdown) to Urea
  - Storage of iron, vitamins and trace elements
  - Drug Detoxification, Metabolism, Transport
    - Most drugs interact with one or more SLC or ABC transporter proteins for entry or exiting hepatocytes
    - Drug-induced liver injury is the most frequent cause of acute liver failure in the United States
Hepatocyte Products and Applications for Drug Metabolism and Transport Studies
Human Liver Tissue for Hepatocyte Isolation

- All human tissue materials originate from US Organ Procurement Organizations. Informed consent for research use has been provided.
- Livers rejected for organ transplant.
- Obtain medical history of the donor and serologies. Only donors which meet certain criteria are accepted. Internal processes are in place to ensure that details which can identify the patient are eliminated.
- Prior to use in cryopreserved hepatocytes, tissue is tested by PCR for HIV1/2, HBV, HCV, HTLV1/2 and CMV.
Hepatocyte Isolation

Human Liver → Perfusion → Enrichment

PRODUCTS
- suspension
- freshly plated
- cryopreserved

Viability & Yield Measurements

BD
Advantages and Disadvantages

• **Advantages**
  – Considered the Gold Standard model for metabolism studies
  – Contain all the hepatic enzymes, including transporters and co-factors (NADPH, UDPGA, GSH, PAPS etc.) needed for drug metabolism/hepatic transport studies
  – Studies typically carried out with Hepatocytes include:
    • Enzyme induction
    • Metabolite ID
    • Drug transport studies (uptake and efflux)
    • Toxicity studies
    • DDI studies (recent application)

• **Disadvantages**
  – Loss of viability for cells in suspension.
  – Lose P450 enzyme expression within 2-3 days of plating
  – Not all lots of cryopreserved hepatocytes will replate
  – Variability between levels of P450 activity between human donors
Human Hepatocyte Products and Applications

- Hepatocytes are prepared from fresh human livers (organ donors)
- Hepatocytes are sold as:
  - Fresh cells on tissue culture plates
    - Primarily used for Induction studies
    - Drug efflux studies (with sandwich culture)
  - Fresh cells in suspension
    - Metabolic stability, transport studies
    - Metabolite ID
  - Cryopreserved hepatocytes (more convenient vs fresh cells)
    - Metabolic stability (drug half-life); characterized for all the major CYPs and UGTs
    - Drug uptake studies; characterized for important SLC uptake transporters
    - Cryopreserved hepatocytes that plate
      - CYP induction studies (CYP3A4, 1A2 and 2B6)
      - Drug efflux studies using sandwich culture (P-gp, MRP2, BSEP)
      - Metabolic stability studies (slowly metabolized drugs requiring long incubation period in order to observe metabolites)
CYP Induction Procedures (Hepatocyte Model)

Culture hepatocytes (2-3 days)

Treat with test drugs or positive inducers (3 days)

Harvest cells

Add substrates

mRNA

- Northern blot
- RT/PCR

Microsomes

- Western blot
- Enzyme activity

Enzyme activities

Fluorescence

HPLC
Comparison of Fresh vs. Cryopreserved Hepatocytes on 3A4 Induction
BD Matrigel Matrix Overlay Format for Efflux Transporter Studies

- Hepatocyte collagen/BD Matrigel matrix sandwich culture
- Plated hepatocytes in sandwich culture form Biliary Canaliculi and express major efflux ABC transporter proteins (P-gp, MRP2, BSEP)
- BD Matrigel matrix overlay procedure
- Prepare BD Matrigel matrix solution on ice: 0.25mg/mL in overlay medium (WME)
  - BD Matrigel matrix/WME mixture should be added to cells on day 1, after 2-4 hour incubation in Hepatocyte Culture medium
  - Add BD Matrigel matrix /WME mixture to cells @ 500ul/well (0.25mg/ml)
  - Incubate the plates 5% CO2 at 37oC over night
  - Replace BD Matrigel matrix/WME with Hepatocyte Culture Medium and proceed to application (e.g. CYP induction or drug efflux assays)
Applications for Hepatocyte Sandwich Cultures

- BD Matrigel matrix sandwich cultures can improve cell morphology and health
- CYP basal activity (in absence of inducer) is generally higher with sandwich culture format
- Sandwich culture is required for the formation of biliary canaliculi
  - Supports biliary efflux assays (P-gp, MRP2 and BSEP are expressed on apical membrane in sandwich environment)
Accumulation of BSEP Fluorescent Substrate (CLF) in Bile Canaliculi

BD Gentest human cryopreserved hepatocytes (lot 141)

Choly Lysyl Fluorescein
Thawing and Plating Methods for Cryopreserved Hepatocytes

Density Gradients
Considerations for Choosing a Thawing/Plating Method

- Method should be fast (as few steps as is possible to minimize loss in cell viability and save researchers time)
- Non-toxic to cells, no changes to hepatocyte physiological function
- Maximize cell viability and recovery
  - Traditional methods generally use a density gradient to remove dead cells (e.g. Percoll™)

Percoll™ is a trademark of GE Healthcare
Cryopreserved Hepatocyte Plating Methods

• Direct plating
  – Fast
  – DMSO is included when plating
  – Low viability, large amount of dead cells effect cell attachment

• Cell Culture Media
  – DMSO is removed
  – One-step centrifugation step
  – Low to Moderate viability; high recovery
  – Can have significant amount of dead cells which can effect cell attachment

• Percoll Purification Media
  – High viability and low/moderate recovery
  – Generally employs two centrifugation steps
  – Percoll can be cytotoxic to certain cell types, e.g. sperm cells
    • High endotoxin levels and unstable PVP coating
    • Contaminating PVP can impact plating efficiency

• The new BD Gentest™ High Viability Recovery Kit
  – Proprietary non-cytotoxic recovery media
  – Low endotoxin levels
  – One centrifugation step
  – Superior viability and recovery (vs Percoll™)
  – Maximizes cell plating efficiency
Density Gradient Centrifugation

Sedimentation rate:
- Proportional to the difference between the density of the particle and that of the surrounding media
- Proportional to particle size.

Hepatocyte:
- Live cells are dense, while dead cells are light
- A gradual decrease in density when cells die
- Different sizes

In general, as the density of the media increases, the viability increases, but yield will decrease
Percoll™: Silica coated by Polyvinylpyrrolidone (PVP)

Extra wash cell loss
Free PVP (1-2%): cytotoxic
Endotoxin level > 6EU/ml
Aggregate Crystals formed on the plates

Other cell damaging effects: possible membrane alterations, induce inflammatory responses.

BD Gentest™ High Viability Recovery Medium for Plating Cryopreserved Hepatocytes
BD Gentest High Viability Recovery Kit: *Non-cytotoxic recovery medium*

- A ready-to-use kit
- 2 tubes of Recovery Media (45 mL)
- 2 tubes of Plating Media (45 mL)
- Data sheet and instructions on how to use
How to Use the Kit for Plating Cells

1. Add 5 mL FBS to the Plating Media tube, warm the Recovery Media and Plating Media to 37°C.
2. Thaw human cryohepatocytes in 37°C water bath, transfer the contents to the Recovery Media tube, rinse the vial with Recovery Media and combine the wash.
3. Centrifuge at 100 g for 10 minutes (middle acc/low brake).
4. Aspirate the supernatant, resuspend the cell pellet in 2 mL of Plating Media/10% FBS.
5. Measure volume and cell viability / recovery.
6. Plate cells on 24-well collagen I coated plate @ 400,000/well.
7. Incubate cells with 5% CO₂ at 37°C for 2-4 hours for initial attachment.
8. Feed cells with BD™ hepatocyte culture medium @ 400 µL/well and incubate overnight with 5% CO₂ at 37°C.
9. CYP Induction assays should be initiated on day 2, after confluent monolayer has formed.
• Cells will not be completely adherent after 2 hours, but they should be attached and be in the process of spreading.

• After 24 hours, cells should be in cuboidal morphology.

• Cryopreserved cells need to be used right away for induction assays.
Cell Monolayer Examples

Not all lots of cryopreserved hepatocytes will plate

Lot did not pass plating criteria

Lot 114 passed plating criteria and QC.
### BD Gentest High Viability CryoHepatocyte Recovery Kit (vs BD Percoll-based purification kit)

For 10 representative BD inducible lots:

- Viability increases on average 7% \((p<0.05, \ n=10)\)
- Recovery increases on average 1.7 Million/vial, a 25% increase

<table>
<thead>
<tr>
<th>Lot Number</th>
<th>Delta Viability (%)</th>
<th>Recovery Improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>266</td>
<td>3.0</td>
<td>(1.7M/vial, 25%)</td>
</tr>
<tr>
<td>267</td>
<td>2.5</td>
<td></td>
</tr>
<tr>
<td>228</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>264</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>178</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>166</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>260</td>
<td>0.0</td>
<td></td>
</tr>
<tr>
<td>246</td>
<td>-0.5</td>
<td></td>
</tr>
<tr>
<td>262</td>
<td>-1.0</td>
<td></td>
</tr>
<tr>
<td>195</td>
<td>-1.5</td>
<td></td>
</tr>
</tbody>
</table>

**Average:**
- Viability: 7%
- Recovery: 1.7M/vial, 25% increase
BD Gentest Inducible-Qualified Human CryoHepatocytes Inventory

- > 80% post-thaw viability for all lots. Average viability: 89%
- The increases of viability and recovery with the new high viability kit are both statistically significant (vs Percoll media)

<table>
<thead>
<tr>
<th>Catalog No.</th>
<th>BD Lot No.</th>
<th>Donor Number</th>
<th>High Viability Recovery Kit</th>
<th>Viability</th>
<th>Recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td>454550</td>
<td>142</td>
<td>HH224</td>
<td>95%</td>
<td>6.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>193</td>
<td>HF281</td>
<td>93%</td>
<td>6.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>118</td>
<td>HH199</td>
<td>87%</td>
<td>4.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>170</td>
<td>HH253</td>
<td>86%</td>
<td>3.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>258</td>
<td>HMC414</td>
<td>86%</td>
<td>3.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>262</td>
<td>HFC418</td>
<td>95%</td>
<td>6.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>264</td>
<td>HFC422</td>
<td>91%</td>
<td>7.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>277</td>
<td>HFC438</td>
<td>89%</td>
<td>7.0</td>
<td></td>
</tr>
</tbody>
</table>

| 454551      | 106        | HH187        | 92%                        | 5.3       |
|             | 141        | HH223        | 88%                        | 14.9      |
|             | 166        | HH248        | 93%                        | 7.9       |
|             | 94         | HH177        | 83%                        | 5.1       |
|             | 107        | HH188        | 81%                        | 6.2       |
|             | 195        | HF284        | 90%                        | 9.4       |
|             | 178        | HH261        | 90%                        | 8.9       |
|             | 178*       | HH261        | 90%                        | 7.6       |
|             | 226        | HF373        | 80%                        | 17.3      |
|             | 228        | HF382        | 90%                        | 7.5       |
|             | 246        | HMC402       | 86%                        | 12.9      |
|             | 260        | HMAAP416     | 90%                        | 10.1      |
|             | 266        | HMC424       | 88%                        | 6.9       |
|             | 267        | HFC425       | 83%                        | 6.5       |
|             | 271        | HMC429       | 88%                        | 7.9       |
|             | 276        | HFA437       | 90%                        | 8.0       |
|             | 281        | HFC443       | 90%                        | 7.7       |
Plating Efficiency

High Viability Recovery Kit

Lot 281
24 hr, 100X
Confluency: 95%

Lot 261
24 hr, 100X
Confluency: 85%

Lot 261
96 hr, 100X
Confluency: 85%

Percoll Purification

95%
80%
33
75%

• BD Gentest high viability cryohepatocyte recovery kit maximizes plating efficiency for some lots
Midazolam Metabolism Assay

Lot 281

<table>
<thead>
<tr>
<th>Recovery Media</th>
<th>% Viability</th>
<th>Yield, E6/vial</th>
<th>24h, % Conflency</th>
<th>MDZ, CL, ml/hr/e6 cell</th>
<th>% MDZ remaining @8h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell Culture Media</td>
<td>73</td>
<td>8.4</td>
<td>90</td>
<td>0.222</td>
<td>8</td>
</tr>
<tr>
<td>Percoll</td>
<td>80</td>
<td>5.6</td>
<td>85</td>
<td>0.201</td>
<td>9.3</td>
</tr>
<tr>
<td>The New Media</td>
<td>83</td>
<td>6.8</td>
<td>90</td>
<td>0.204</td>
<td>5.1</td>
</tr>
</tbody>
</table>

- All three methods gave similar results for Midazolam Clearance

24-hr Cell Morphology and Confluency (24 h, 20X)

Cell Culture Media

The New High Viability Media

Percoll Purification Media
3A4 Induction Assays

- 3A4 induction assay results are consistent (tested on 3 lots)
**Number of Vials which can be Processed per 45 mL Recovery Medium**

Up to 5 vials can be processed per tube of recovery media.

<table>
<thead>
<tr>
<th>vials / tube</th>
<th>Lot 251</th>
<th>Lot 247</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Viability (%)</td>
<td>Recovery (M/vial)</td>
</tr>
<tr>
<td>1</td>
<td>84.2</td>
<td>6.7</td>
</tr>
<tr>
<td>2</td>
<td>84.5</td>
<td>7.4</td>
</tr>
<tr>
<td>3</td>
<td>83.9</td>
<td>6.8</td>
</tr>
<tr>
<td>4</td>
<td>81.3</td>
<td>6.6</td>
</tr>
<tr>
<td>5</td>
<td>81.3</td>
<td>6.8</td>
</tr>
<tr>
<td>6</td>
<td>78.4</td>
<td>6.5</td>
</tr>
</tbody>
</table>

Greater than 5 vials (6) of cryopreserved hepatocytes per tube of recovery media demonstrated a 5% drop in viability.
Lot-to-lot Consistency

Viability is within 4% with 3 different lots

<table>
<thead>
<tr>
<th>Lot 178</th>
<th>Lot 246</th>
<th>Lot 260</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kit Lot 1</td>
<td>89.0</td>
<td>83.9</td>
</tr>
<tr>
<td>Kit Lot 2</td>
<td>88.6</td>
<td>85.7</td>
</tr>
<tr>
<td>Kit Lot 3</td>
<td>85.4</td>
<td>84.9</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lot 178</th>
<th>Lot 246</th>
<th>Lot 260</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kit Lot 1</td>
<td>6.89</td>
<td>10.85</td>
</tr>
<tr>
<td>Kit Lot 2</td>
<td>6.71</td>
<td>11.45</td>
</tr>
<tr>
<td>Kit Lot 3</td>
<td>8.44</td>
<td>10.65</td>
</tr>
</tbody>
</table>
Primary criteria is viability - indicative of cell health and ability of cells to attach.

<table>
<thead>
<tr>
<th></th>
<th>Lot 142</th>
<th>Lot 170</th>
<th>Lot 261</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Viability (%)</td>
<td>Recovery (M/vial)</td>
<td>Viability (%)</td>
</tr>
<tr>
<td>High Viability Recovery Kit</td>
<td>95</td>
<td>7.3</td>
<td>84</td>
</tr>
<tr>
<td>BD Percoll Kit</td>
<td>90</td>
<td>3.7</td>
<td>81</td>
</tr>
<tr>
<td>Competitor 1</td>
<td>91</td>
<td>7.5</td>
<td>74</td>
</tr>
<tr>
<td>Competitor 2</td>
<td>64</td>
<td>9.1</td>
<td>49</td>
</tr>
</tbody>
</table>
Summary

• Several methods exist for thawing and plating cryopreserved hepatocytes
  – Individual methods generally not optimized for all critical features: speed/ease-of-use, non-cytotoxic, high viability, and high recovery, etc.

• Cell viability, recovery and plating efficiency tended to vary the most between the various methods, while fold-induction and metabolic activity varied the least.

• BD Gentest high viability recovery medium showed improved viability and cell recovery compared to conventional methods such as Percoll density gradients.
Questions?

Contact information:
e-mail: chris_patten@bd.com

Technical Support:
In the U.S.
tel: 877.232.8995 or or 978-901-7491
e-mail: labware@bd.com
Outside the U.S.
Contact your local distributor or visit bdbiosciences.com/offices to locate your nearest BD Biosciences office.

For research use only. Not intended for use in diagnostic or therapeutic procedures.
BD, BD Logo, and all other trademarks are property of Becton, Dickinson and Company. ©2010 BD